StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of TTNP stock opened at $5.54 on Friday. The firm’s 50 day moving average price is $5.84 and its 200-day moving average price is $6.52. Titan Pharmaceuticals has a one year low of $4.24 and a one year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
